Tuberous sclerosis - What's new?

Archives of Disease in Childhood

Volumn 93, Issue 9, 2008, Pages 728-731

  Osborne, John P ^a,b   Merrifield, Jane ^a   O'Callaghan, Finbar J K ^a,c,d  

^a ROYAL UNITED HOSPITALS BATH NHS FOUNDATION TRUST   (United Kingdom)

^b University of Bath   (United Kingdom)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; RAPAMYCIN; VIGABATRIN;

ASTROCYTOMA; DISEASE ASSOCIATION; DISEASE SEVERITY; EPILEPSY; GENE; GENE MUTATION; GENETIC COUNSELING; GENETIC VARIABILITY; HUMAN; HYPERLIPIDEMIA; INFANTILE SPASM; INTERSTITIAL PNEUMONIA; MOUTH ULCER; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SYMPTOMATOLOGY; TSC1 GENE; TSC2 GENE; TUBEROUS SCLEROSIS; VISUAL DISORDER;

ANTICONVULSANTS; FEMALE; GENETIC COUNSELING; HUMANS; MALE; MUTATION; TREATMENT OUTCOME; TUBEROUS SCLEROSIS;

EID: 51449115677     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.2006.094938     Document Type: Review

References (31)

1. Webb DW, Fryer AE, Osborne JP. Morbidity associated with tuberous sclerosis: a population study. Dev Med Child Neurol 1996;38:146- 55.
2. Webb DW, Thomas RD, Osborne JP. Cardiac rhabdomyomas and their association with tuberous sclerosis. Arch Dis Child 1993;68:367- 70.
3. Webb DW, Clarke A, Fryer A, et al. The cutaneous features of tuberous sclerosis: a population study. Br J Dermatol 1996;135:1-5.
4. O'Callaghan FJ, Noakes MJ, Martyn CN, et al. An epidemiological study of renal pathology in tuberous sclerosis complex. BJU Int 2004;94:853-7.
5. Rowley SA, O'Callaghan FJ, Osborne JP. Ophthalmic manifestations of tuberous sclerosis: a population based study. Br J Ophthalmol 2001;85:420-3.
6. van Slegtenhorst M, de Hoogt R, Hermans C, et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 1997;277:805-8.
7. The European Chromosome 16 Tuberous Sclerosis Consortium. Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell 1993;75:1305-15.
8. Green AJ, Johnson PH, Yates JR. The tuberous sclerosis gene on chromosome 9q34 acts as a growth suppressor. Hum Mol Genet 1994;3:1833-4.
9. Green AJ, Smith M, Yates JR. Loss of heterozygosity on chromosome 16p13.3 in hamartomas from tuberous sclerosis patients. Nat Genet 1994;6:193-6.
10. O'Callaghan FJ, Harris T, Joinson C, et al. The relation of infantile spasms, tubers, and intelligence in tuberous sclerosis complex. Arch Dis Child 2004;89:530-3.
11. DiMario FJ Jr, Diana D, Leopold H, et al. Evolution of cardiac rhabdomyoma in tuberous sclerosis complex. Clin Pediatr (Phila) 1996;35:615-19.
12. Shepherd CW, Gomez MR, Lie JT, et al. Causes of death in patients with tuberous sclerosis. Mayo Clin Proc 1991;66:792-6.
13. Northrup H. Tuberous sclerosis complex: genetic aspects. J Dermatol 1992;19:914-19.
14. Sepp T, Yates JR, Green AJ. Loss of heterozygosity in tuberous sclerosis hamartomas. J Med Genet 1996;33:962-4.
15. van Slegtenhorst M, Nellist M, Nagelkerken B, et al. Interaction between hamartin and tuberin, the TSC1 and TSC2 gene products. Hum Mol Genet 1998;7:1053-7.
16. Tee AR, Fingar DC, Manning BD, et al. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci USA 2002;99:13571-6.
17. Lee L, Sudentas P, Donohue B, et al. Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models. Genes Chromosomes Cancer 2005;42:213-27.
18. van Baal JG, Smits NJ, Keeman JN, et al. The evolution of renal angiomyolipomas in patients with tuberous sclerosis. J Urol 1994;152:35-8.
19. Franz DN, Leonard J, Tudor C, et al. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol 2006;59:490-8.
20. Jones AC, Sampson JR, Hoogendoorn B, et al. Application and evaluation of denaturing HPLC for molecular genetic analysis in tuberous sclerosis. Hum Genet 2000;106:663-8.
21. Verhoef S, Bakker L, Tempelaars AM, et al. High rate of mosaicism in tuberous sclerosis complex. Am J Hum Genet 1999;64:1632-7.
22. Dabora SL, Jozwiak S, Franz DN, et al. Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am J Hum Genet 2001;68:64-80.
23. Bose VM, Au KS, Pollom G, et al. Germ-line mosaicism in tuberous sclerosis: how common? Am J Hum Genet 1999;64:986-92.
24. Chiron C, Dumas C, Jambaque I, et al. Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis. Epilepsy Res 1997;26:389-95.
25. Lux AL, Edwards SW, Hancock E, et al. The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomised trial. Lancet Neurol 2005;4:712-17.
26. Humphrey A, Neville BG, Clarke A, et al. Autistic regression associated with seizure onset in an infant with tuberous sclerosis. Dev Med Child Neurol 2006;48:609-11.
27. Kossoff EH, Thiele EA, Pfeifer HH, et al. Tuberous sclerosis complex and the ketogenic diet. Epilepsia 2005;46:1684- 6.
28. Jarrar HG, Buchhalter JR, Raffel C. Long-term outcome of epilepsy surgery in patients with tuberous sclerosis. Neurology 2004;62:479-81.
29. Connolly MB, Hendson G, Steinbok P. Tuberous sclerosis complex: a review of the management of epilepsy with emphasis on surgical aspects. Childs Nerv Syst 2006;22:896-908.
30. Cross JH. Neurocutaneous syndromes and epilepsy: issues in diagnosis and management. CNS Spectr 2006;11(2 Suppl 2):19-25.
31. Wild JM, Robson CR, Jones AL, et al. Detecting vigabatrin toxicity by imaging of the retinal nerve fibre layer. Invest Ophthalmol Vis Sci 2006;47:917-24.